Clinical Trials
55 trialsNCT07137598 2026-06-01
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Hoffmann-La Roche
Phase 2 Recruiting
NCT06712628 2026-02-17
UP-RISING
AbbVie
Recruiting
NCT03270982 2025-12-23
Comprehensive Segmental Revision System
Zimmer Biomet
Active not recruiting
NCT05413044 2025-12-08
A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) Register
Bristol-Myers Squibb
Completed
NCT05421442 2025-12-08
DANBIO
Bristol-Myers Squibb
Completed
NCT05796245 2025-06-04
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
Pfizer
Completed
NCT05615246 2025-01-27
HRP
Exactech
Terminated
NCT06583395 2024-11-01
QUANTUM
VitaMed Research LLC
Enrolling by invitation
NCT03016013 2024-09-26
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
RemeGen Co., Ltd.
Phase 3 Completed
NCT06175338 2024-09-19
Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis
Mabscale, LLC
Phase 1 Active not recruiting
NCT01242488 2024-07-17
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
UCB Pharma
Phase 2 Completed
NCT04721821 2024-04-12
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
Pfizer
Completed
NCT03120949 2023-10-12
CREDO 4
R-Pharm
Phase 3 Completed
NCT02760433 2023-09-21
CREDO 3
R-Pharm
Phase 3 Completed
NCT02822495 2023-06-15
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Atara Biotherapeutics
No longer available
NCT00048321 2022-12-05
ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis
Ionis Pharmaceuticals, Inc.
Phase 2 Completed
NCT03670667 2022-05-18
A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents
Bristol-Myers Squibb
Completed
NCT03449758 2022-04-28
SariPRO
Sanofi
Phase 4 Completed
NCT03663829 2022-03-09
Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia
Bristol-Myers Squibb
Completed
NCT01960855 2021-08-24
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
AbbVie
Phase 2 Completed
NCT02092467 2021-08-17
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
Phase 4 Completed
NCT01764321 2020-12-22
NexT
UCB Pharma
Completed
NCT03348046 2020-03-04
PASSRRA
Hikma Pharmaceuticals LLC
Completed
NCT03001219 2020-01-29
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
Hoffmann-La Roche
Phase 2 Terminated
NCT01721044 2019-09-18
RA-BEACON
Eli Lilly and Company
Phase 3 Completed
NCT02882087 2019-04-03
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
RemeGen Co., Ltd.
Phase 2 Terminated
NCT00960440 2018-12-19
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
Pfizer
Phase 3 Completed
NCT02046603 2018-12-07
ACT-MOVE
Hoffmann-La Roche
Phase 3 Completed
NCT02679001 2018-07-26
A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.
Hoffmann-La Roche
Completed
NCT02862574 2018-06-27
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
Gilead Sciences
Phase 2 Terminated
NCT00503425 2017-08-15
A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.
Hoffmann-La Roche
Phase 3 Completed
NCT01362062 2017-08-02
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Hoffmann-La Roche
Completed
NCT00357903 2017-02-09
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials
Amgen
Phase 3 Completed
NCT01715896 2016-10-31
A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
MedImmune LLC
Phase 2 Completed
NCT00468546 2016-10-25
A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy
Hoffmann-La Roche
Phase 3 Completed
NCT01613027 2016-10-24
An Observational Study of MabThera in Participants With Severe Active Rheumatoid Arthritis
Hoffmann-La Roche
Completed
NCT01641952 2016-08-17
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent
Hoffmann-La Roche
Completed
NCT01309282 2016-08-12
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)
Hoffmann-La Roche
Completed
NCT02519387 2016-07-20
Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity
Mundipharma Pharmaceuticals Sdn. Bhd.
Phase 4 Completed
NCT01350804 2016-05-23
NURTURE 1
Novartis
Phase 3 Completed
NCT01390545 2016-04-13
VELVET
Takeda
Phase 2 Terminated
NCT00595413 2016-02-17
AUGUST II
EMD Serono
Phase 2 Completed
NCT01069419 2015-10-29
FasT
UCB Pharma
Completed
NCT00724672 2015-06-01
A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521)
Merck Sharp & Dohme LLC
Withdrawn
NCT00883753 2014-08-06
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
Hoffmann-La Roche
Phase 3 Completed
NCT00361335 2014-07-29
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Centocor, Inc.
Phase 3 Completed
NCT00440817 2014-04-10
An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.
Centocor Ortho Biotech Services, L.L.C.
Completed
NCT01283971 2014-02-10
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
Hoffmann-La Roche
Phase 4 Terminated
NCT01463059 2013-03-25
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
UCB Pharma
Phase 2 Completed
NCT01294722 2013-03-19
A Study to Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti-Tumor Necrosis Factor α (TNFα) in a General Hospital Setting in Korea
Janssen Korea, Ltd., Korea
Completed